Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30832481 | 0.99 | MEN1 (0.50) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL21595431 | 0.89 | NPC1 (0.46) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL24221032 | 0.89 | MEN1 (0.53) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL18712918 | 0.87 | RET (0.48) | — | |
| SCHEMBL6515271 | 0.84 | MEN1 (0.50) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL18705193 | 0.83 | — | — | |
| SCHEMBL73672 | 0.83 | MEN1 (0.47) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL19011877 | 0.82 | TSHR (0.44) | MEN1KMT2ANPSR1 | |
| SCHEMBL536304 | 0.82 | MEN1 (0.48) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL4814906 | 0.82 | MEN1 (0.48) | MEN1KMT2ANPSR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002522389-A | — | — | 2002-07-23 | — | — | JP | claimed |
| EP-1102590-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING OR PREVENTING ABNORMAL BONE RESORPTION | MERCK SHARP & DOHME LTD. (GB) | 2001-05-30 | — | — | EP | claimed |
| WO-2000007598-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING OR PREVENTING ABNORMAL BONE RESORPTION | MERCK SHARP & DOHME LIMITED (GB) | 2000-02-17 | — | — | WO | claimed |
| EP-1102590-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING OR PREVENTING ABNORMAL BONE RESORPTION | MERCK SHARP & DOHME LTD. (GB) | 2001-05-30 | — | — | EP | disclosed |
| EP-1079863-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LTD. (GB) | 2001-03-07 | — | — | EP | disclosed |
| WO-2000007598-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING OR PREVENTING ABNORMAL BONE RESORPTION | MERCK SHARP & DOHME LIMITED (GB) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999059635-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LIMITED (GB) | 1999-11-25 | — | — | WO | disclosed |